Skip to content

The Policy Vault

Methodology Why Contact

Coverage / Medica / Jakafi (ruxolitinib) / Acute Lymphoblastic Leukemia

Jakafi (ruxolitinib) — Medica

Acute Lymphoblastic Leukemia

Initial criteria

age < 21 years
mutation/pathway is Janus Associated Kinase (JAK)-related

Approval duration

1 year

Provenance

View official policy PDF

Plan: Medica
Drug: Jakafi (ruxolitinib)
Indication: Acute Lymphoblastic Leukemia
Last seen: 2025-10-06
Hash: 14ac0d4bf7fe…

Disclaimer: Educational only. Coverage varies by employer group and formulary. Always verify with the plan.

Consult

Curious about trends across plans?

I can walk you through how this policy compares and share data-backed patterns. Short call, straight answers.

Email to start a quick consult What I cover (overview)

No commitments—just a brief conversation to see if it’s helpful.

The Policy Vault

Structured prior authorization and step-therapy criteria for commercial health plans. Built by pharmacists for healthcare professionals.

Disclaimer: Educational use only. Coverage varies by employer group and formulary. Always verify with the plan.

Product

Coverage Directory
Why Policy Vault
Methodology

Company

Contact
Press
Support

© 2025 The Policy Vault. Data sourced from official health plan documents.